We all probably know the basics. Cannabidiol, CBD, is the non-pyschoactive cannabinoid found in cannabis – it won’t get you high. Certain strains have a high percentage of CBD naturally present in the plant, such as Harlequin, Charlotte’s Web and BMF’s new strain Canna-Tsu. A plant is considered “high-CBD” is the plant is 4% or higher CBD dry-weight. Originally only derived from Cannabis sativa, Cannabidiol can be found in some indica-dominant strains. If you see high CBD indica for sale, you can bet it is a hybrid.
Customers seeking CBD are looking for relaxation without head high and tend to come from the medical market. CBD is being researched as a treatment for such ailments as epilepsy, inflammation, pain and anxiety. Most CBD products are sold in ratios, allowing people to get a blend of the effects from both THC and CBD.
So where is the misconception? CBD, while not high-inducing or considered addictive, is regulated right along with THC as a Schedule 1 drug.
CBD can be derived from any portion of the plant, and as such has been sold in the U.S. after harvest from legally imported industrial hemp stalks and leaves for many years. This clever interpretation of the law blossomed into an online market of “CBD only” products, sold across state lines and not regulated or tested in the same fashion as the cannabis-derived CBD that you might find at your local dispensary. These products most likely contain trace amounts of THC, causing the DEA to treat them like any other cannabis product – federally illegal. So take care when selling to your out-of-state visitors. Cannabis – even CBD – should never cross a state line.
For more on the DEA’s clarification of CBD scheduling, click here.